We bring to your notice a new website where you can buy kamagra jelly australia at a low cost with fast delivery to Australia.
Phase ii open study of ketoconazole as an inhibitor of enzyme
PHASE II OPEN STUDY OF KETOCONAZOLE AS AN INHIBITOR OF ENZYME
CYP17 LOCALLY ADVANCED OR DISSEMINATED GRANULOSA CELL OVARIAN
CANCER. GREKO (GRANULOSA ET KETOCONAZOLE) STUDY
: 2012-001948-21 RATIONALE
Granulosa cell tumours of the ovary are a very uncommon entity. Since 2009 we have been aware that 100% of the cases present a mutation in the FOXL2 gene, which has a protein that indirectly regulates expression of the CYP17 enzyme. This enzyme has been used as a therapeutic target in prostate cancer, so similar results could be obtained in this pathology. The GREKO trial sets out to establish the potential activity of an enzyme CYP17 inhibitor, ketoconazole, in ovarian granulosa cell tumours.
• Patients who have given their written informed consent
• Diagnosis of histologically confirmed ovarian granulosa cell carcinoma
• Availability of sufficient biopsy material for confirmation of the diagnosis by a
central pathologist and determination of the FOXL2 402C→G (C134W) mutation.
• Patients with adequate hepatic function, defined by:
- AST and ALT serum values ≤ 3 x ULN (except in the presence of
metastasis, when values ≤ 5 x ULN) will be permitted
• Patients with adequate bone marrow function, defined by:
- Absolute neutrophil count ≥1.5 x 109/L,
• Patients with adequate renal function: serum creatinine ≤1.5 x ULN
• Absence of any impediment to compliance with the study protocol
• Sexually active women of fertile age, not subjected to hysterectomy or double
adnexectomy, have to comply with the following contraception instructions:
- Pregnancy test in serum or urine negative in the 72 hours prior to the start
- Use of medically accepted contraceptive method during: the 2 months prior
to the start of the study treatment, during the study, 3 months after the last treatment dose.
• Patients with primary tumour 2 years prior to starting with the investigational
drug, with the exception of properly treated or wholly removed uterine cervix carcinoma in situ or basal cell carcinoma or superficial bladder carcinoma.
• Patients who have received radical radiotherapy ≤ 4 weeks prior to starting the
study treatment or who have not recovered from the toxicities of radiotherapy. Palliative radiotherapy for painful bone lesions is permitted up to 14 days prior to the start of the investigational treatment.
• Patients with heart failure or clinically significant heart disease, including any of
- History or presence of uncontrolled severe ventricular arrhythmias.
- Clinically significant bradycardia at rest.
- LVEF <45% assessed by 2-D echocardiogram (ECO) or MUGA. These
tests, however, are not compulsory under the protocol.
- Any of the following diseases in the 6 months prior to the start of the
• Myocardial infarction (MI), severe or unstable angina, coronary
revascularization, congestive cardiac insufficiency (CCI), cerebrovascular accident (CVA), transitory ischemic attack (TIA)
• Patients with gastrointestinal function failure or with gastric disease causing
significant alteration in ketoconazole absorption, such as for instance: severe ulcerous diseases, uncontrolled nauseas, vomiting, diarrhoea, poor absorption syndrome, extensive small bowel resection (>1m) or inability to swallow oral medication. Prior partial or total gastrectomy is not an exclusion criterion.
• Diagnosis of human immunodeficiency virus (HIV) infection.
• Women in fertile age not using an effective method of contraception
• Patients who do not wish to or are unable to comply with the protocol.
CONTACT DATA, PARTICIPATING RESEARCH CENTRES
Juan L Sanz
• COORDINATING INVESTIGATOR
Centro Integral Oncológico Clara Campal
Coordinating investigator: Jesus Garcia-Donas, MD +34 91 267 50 62
• PARTICIPATING HOSPITALS
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, 15706
Principal investigator: Juan F Cueva, MD +34 988385471 Hospital Central de Asturias
Oviedo, Asturias, 33006
Principal investigator: Emilio García Esteban, MD +34 985108000 Hospital Universitario Fundación Alcorcón
Alcorcón, Madrid, 28922
Principal investigator: Alicia Hurtado, MD +34 666383649 Hospital del Mar
Principal investigator: Laia Garrigos, MD +34 93 248 30 00 Hospital Reina Sofía
Principal investigator: Maria J Rubio, MD +34 957 010 000 Hospital La Paz
Principal investigator: Andrés Redondo, MD +34 917277000 ext 41138 Hospital Morales Meseguer
Principal investigator: Elena García, MD +34 96836520 Complejo Hospitalario de Navarra
Principal investigator: Nuria Lainez, MD Hospital Son Llatzer
Palma de Mallorca, 07198
Principal investigator: Isabel Bover, MD 871202184 Hospital Universitario y Politécnico La Fe
Principal investigator: Ana Santaballa, MD +34 966616487 Sponsor
: Spanish Group for Research on Orphan and Uncommon Tumours (GETHI) Financing Entity:
Ministry of Health,
announcement of grants for fomenting independent clinical research 2011 (project
Bidkar et al., IJPRD, 2011; Vol 3(3):10; May 2011 (69 - 72) International Standard Serial Number 0974 – 9446 -------------------------------------------------------------------------------------------------------------------------------------------------- ANTHELMENTIC ACTIVITY OF CITRUS AURANTIUM LINN. Bidkar J S 1*, Bhujbal M D1, ABSTRACT Correspondence to Author Pres
Checklist gender perspective Use This checklist follows the structure of the list for quality criteria. It enables you not only to test the de- gree of your gender sensitivity but you can also identify areas of your work where a gender approach can be introduced. If you use this checklist periodically, if you really set out to exploit the potential for improvement and implement corresp